Thomas Brown
University of Texas MD Anderson Cancer Center
35 Papers
532 Citations
Thomas Brown is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Hepatocellular carcinoma. The author has an hindex of 21, co-authored 35 publications. Previous affiliations of Thomas Brown include University of Arizona.
Chat about Author
Papers
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
Melanie B. Thomas,Romil Chadha,Katrina Y. Glover,Xuemei Wang,Jeffrey S. Morris,Thomas Brown,Asif Rashid,Janet Dancey,James L. Abbruzzese +8 more
TL;DR: The proportion of hepatocellular carcinoma patients treated with erlotinib who were alive and progression-free (PFS) at 16 weeks of continuous treatment was determined.
Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: A Hospital-Based
Yasser H. Shaib,Hashem B. El-Serag,Ajay K. Nooka,Melanie B. Thomas,Thomas Brown,Yehuda Z. Patt,Manal M. Hassan +6 more
- 01 Jan 2007
TL;DR: In this article, the authors identified 246 cases (83 ICC and 163 ECC) and matched them to 236 controls, finding that ICC patients had a higher prevalence of anti-HCV antibodies (6.0% vs 0.8%, P = 0.0001), and heavy alcohol consumption (21.7% vs 3.8%), compared with controls.
237
Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States.
Manal M. Hassan,Ahmed Kaseb,Donghui Li,Yehuda Z. Patt,Jean Nicolas Vauthey,Melanie B. Thomas,Steven A. Curley,Margaret R. Spitz,Steven I. Sherman,Eddie K. Abdalla,Marta L. Davila,Richard D. Lozano,Deena M. Hassan,Wenyaw Chan,Thomas Brown,James L. Abbruzzese +15 more
TL;DR: A significant elevated risk association between hypothyroidism and HCC in women that was independent of established HCC risk factors was noted, with an approximate two‐fold to three‐fold increased risk of HCC development.
161
Limitations of conventional doses of chemoradiation for unresectable biliary cancer
Christopher H. Crane,Kenneth O. MacDonald,Jean Nicolas Vauthey,Patt Yehuda,Thomas Brown,Steven A. Curley,Adrian Wong,Marc E. Delclos,Chusilp Charnsangavej,Nora A. Janjan +9 more
TL;DR: Although the small patient numbers limited the statistical power of this study, a suggestion of improved local control was found with the use of higher RT doses, and future prospective investigation using high-dose conformal RT with novel cytotoxic and/or biologic agents with radiosensitizing properties is warranted.
138
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.
Sunil Krishnan,Nora A. Janjan,John M. Skibber,Miguel A. Rodriguez-Bigas,Robert A. Wolff,Prajnan Das,Marc E. Delclos,George J. Chang,Paulo M. Hoff,Cathy Eng,Thomas Brown,Christopher H. Crane,Barry W. Feig,Jeffrey S. Morris,Saroj Vadhan-Raj,Stanley R. Hamilton,Edward H. Lin +16 more
TL;DR: This regimen of radiotherapy plus capecitabine is well tolerated and is more convenient than protracted venous infusion of 5-FU for LARC.
123